Ustekinumab linear clearance was in range of reported clearance values in other studies in IBD [37,38,39], and the TMDD PK model is consistent with the recent findings of the TNF-mediated PK of infliximab in ulcerative colitis [40]. Here, TNF is linked to ulcerative colitis.